The outcomes of patients with left ventricular (LV) dysfunction and secondary mitral regurgitation (SMR) are still controversial.
S econdary mitral regurgitation (SMR) occurs when normal or almost normal mitral leaflets are prevented from adequate coaptation by underlying left ventricular (LV) dysfunction, mitral annular dilation, or both. It is the most common valve disease, with an incidence of less than 1% before age 55 years but reaching 9% after age 75 years. 1 Secondary mitral regurgitation is generally divided into SMR due to ischemic heart disease or nonischemic cardiomyopathies, although it can also be a consequence of chronic atrial enlargement. In ischemic heart disease, even mild SMR has been shown to increase mortality. [2] [3] [4] In the Survival and Ventricular Enlargement (SAVE) 5 trial, patients with SMR were more likely to experience cardiovascular mortality and severe heart failure (HF) than those without SMR. Grigioni et al 2 showed adjusted relative risks of total and cardiac mortality associated with the presence of ischemic mitral regurgitation (MR) of 1.88 and 1.83, respectively, compared with patients without ischemic MR. The results from an MR substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) 6 trial confirmed the previous observational studies, demonstrating an adverse prognosis of untreated ischemic MR in a cohort of patients with ischemic cardiomyopathy treated with current guideline-directed medical therapy. However, several other studies [7] [8] [9] [10] [11] did not find that SMR predicted worse survival among patients with ischemia. Similarly, in patients with nonischemic cardiomyopathy, the presence of SMR has been linked to different outcomes, such as death, HF hospitalization, or transplant. In the Beta-blocker Evaluation of Survival Trial (BEST), 12 an MR vena contracta width less than 0.4 cm predicted worse outcomes. Similarly, Cioffi et al 13 and Rossi et al 14 found that SMR was an independent predictor of mortality even in patients without ischemia. On the other hand, studies by Patel et al 15 and Boriani et al 16 did not confirm these results. In the setting of such conflicting findings, we performed a meta-analysis to clarify whether patients with ischemic or idiopathic cardiomyopathies and SMR have an adverse prognosis.
Methods

Literature Search and Study Selection
The study was designed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) requirements. 17 MEDLINE, ISI Web of Science, and Scopus databases were searched for studies published up to March 2017. Studies were identified using the major Medical Subject Headings functional mitral regurgitation OR ischemic mitral regurgitation OR secondary mitral regurgitation combined with outcome OR mortality OR survival. English was set as a language restriction. Two of us (A.S. and P.A.G.) independently examined the title and abstract of citations. The full texts of potentially eligible trials were obtained, and disagreements were resolved by discussion. To identify additional relevant studies, the full text and bibliography of all potential articles were also retrieved in detail. Abstracts, meeting proceedings, and personal communications were not used for the purpose of this study.
Eligibility Criteria
Studies were included if they reported data on outcomes associated with estimation of SMR grade. Studies were excluded if any of the following criteria applied: (1) duplicate publication data, (2) lack of data on SMR grade and its correlation with outcomes, (3) mixed data on SMR and organic MR populations, (4) outcome of interest not clearly reported or impossible to extract or calculate from the published results, and (5) less than 100 patients. The length of follow-up was not set as a restriction.
Data Extraction
Two of us (A.S. and P.A.G.) independently screened articles for fulfillment of inclusion criteria. The baseline characteristics, associations of SMR grade with cardiovascular risk factors, and outcomes were abstracted. Moreover, associations of SMR grade with LV ejection fraction (LVEF) and LV end-systolic volume (LVESV) were also abstracted. Two of us (A.S. and P.A.G.) compared selected trials, and discrepancies were resolved by consensus.
End Points and Definitions
The primary end point (or outcome) of this study was the incidence of all-cause mortality in patients not having SMR compared with patients having SMR. The included studies reported SMR differently; therefore, the primary outcome analysis has been divided into the 3 following sections:
(1) SMR present vs absent detected at echocardiography or ventriculography, (2) SMR detected at echocardiography and qualitatively graded, and (3) SMR detected at echocardiography and quantitatively graded. As secondary end points, we analyzed (1) hospitalization for HF, (2) cardiac mortality, and (3) a composite end point of death, HF hospitalization, and cardiac transplant.
(3) outcome (modality of assessment, enough length of follow-up, and adequacy of follow-up). Based on these criteria, studies with 4 stars for selection, 2 stars for comparability, and 3 stars for outcome were defined as having low risk of bias. Studies with 2 or 3 stars for selection, 1 star for comparability, and 2 stars for outcome were defined as having medium risk of bias. Any study with 1 star for selection or outcome or 0 stars for any of the 3 domains was defined as having high risk of bias.
Statistical Analysis
Two of us (A.S. and P.A.G.) independently extracted for each study the most comprehensively adjusted or unadjusted odds ratios, hazard ratios, and their 95% CIs, as well as the means (SDs). When multiple data were available for the same study, adjusted data were prioritized. Estimates of effect were calculated with a random-effects model and expressed as risk ratios (RRs). Statistical significance was set at P ≤ .05 (2 tailed). Heterogeneity was assessed by Cochran Q statistic and I 2 test.
Significant heterogeneity was considered present for P <.10 or I 2 >50%. Meta-regression analysis was performed to assess the potential influence of important covariates (included in eTable 1 in the Supplement) on between-study heterogeneity (significance at P ≤ .05). 19 If no significant covariates were found to be heterogeneous, the leave-one-out sensitivity analysis was carried out to evaluate the key studies with substantial influence on between-study heterogeneity. 20 Additional sensitivity analyses have been performed for the same purpose, including (1) removal of studies having low risk of bias, (2) removal of studies having moderate to high risk of bias, (3) removal of studies with proximal isovelocity surface area assessment of SMR, and (4) removal of studies reporting unadjusted estimates (eTable 2 in the Supplement). A fixedeffects model was used to confirm the results in case of significant heterogeneity.
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Publication bias was assessed using funnel plots. When significant publication bias was found, it was further explored by Egger test, consisting of a linear regression of the intervention effect estimates on their standard errors, weighting by 1 divided by the variance of the intervention effect estimate.
All data analyses were performed using statistical software. ProMeta (version 2; IDoStatistics) and RevMan (version 5.2; Cochrane Community) were used.
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Results
The initial literature search identified 3820 articles, of which 87 were retrieved for more detailed evaluation, and 53 trials [2] [3] [4] [5] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] (1.4%) were finally included in the study, enrolling 45 900 patients ( Figure 1 and eTable 1 in the Supplement). The mean (SD) length of follow-up in our study population was 40.8 (22.2) months. The LVEF and LVESV values according to SMR grade in the included studies are listed in eTable 3 in the Supplement. As shown, in 26 of 36 studies that reported these data, there was a significant association between LV dysfunction and SMR severity, with higher grades of SMR associated with worse LV function. Figure 2 shows a plot of averaged LVEF values for each grade of SMR. Because severe SMR is uncommon, these studies combined moderate to severe SMR into a single group.
Primary Outcome of All-Cause Mortality
The association between SMR and all-cause mortality was systematically addressed. As summarized in eTable 4 in the Supplement, the detection and grading of SMR differed across the included studies; therefore, the all-cause mortality analysis has been divided into the 3 sections discussed below. 
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SMR Present vs Absent Detected at Echocardiography or Ventriculography
In patients having any degree of SMR, the incidence of all-cause mortality was significantly increased compared with patients not having SMR (17 studies, 2, 3, [7] [8] [9] 26, 27, 30, 31, 36, 41, 43, 46, 48, 52, 53, 55, 63 26 359 patients; RR, 1.79; 95% CI, 1.47-2.18; P < .001, I 2 =85%) ( Figure 3) . When stratifying the analysis for all-cause mortality according to the method used to detect SMR (echocardiography or ventriculography), both subgroups exhibited a significant association between the presence of SMR and allcause mortality, with no difference in the magnitude of the analyzed outcome between the subgroups (χ 2 = 1.89, P for interaction = .17).
SMR Detected at Echocardiography and Qualitatively Graded
In patients having SMR, the incidence of all-cause mortality was significantly increased compared with patients not having SMR (21 studies, 4, 8, 10, 11, 13, 16, 27, 30, 33, 34, 39, [42] [43] [44] 50, 51, 54, 56, 58, 59, 62 21 081 patients; RR, 1.96; 95% CI, 1.67-2.31; P < .001, I 2 = 74%) ( Figure 4) . When stratifying the analysis for allcause mortality according to SMR grading (mild, moderate, and severe), a significant association between the presence of SMR and all-cause mortality persisted in all the subgroups, with a significant difference in the magnitude of the analyzed outcome between subgroups (χ 2 = 11.96, P for interaction = .003).
SMR Detected at Echocardiography and Quantitatively Graded
In patients having SMR, the incidence of all-cause mortality was significantly increased compared with patients not having SMR (9 studies, 3649 patients; RR, 1.97; 95% CI, 1.71-2.27; P < .001, I 2 = 0%) ( Figure 5 ). When stratifying the analysis for all-cause mortality according to the SMR quantification method, a significant association between the presence of SMR and all-cause mortality persisted in all the subgroups, with no difference in the magnitude of the analyzed outcome between subgroups (χ 2 =0. 93,P for interaction = .63). Tcheng et al, 52 1992
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Trichon et al, 53 2003
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Shown are random-effects risk ratios and 95% CIs for all-cause mortality according to the SMR detection method used. subgroups demonstrated a significant association between the presence of SMR and HF hospitalization, with no differences between subgroups (χ 2 = 0.73, P = .70).
Cardiac Mortality
The incidence of cardiac mortality was significantly higher in patients having any SMR compared with patients not having Ellis et al, 4 2002 Engström et al, 30 2010 Feinberg et al, 33 2000 Hillis et al, 11 2005 Mentias et al, 44 2017 MacHaalany et al, 43 2014 Test for overall effect: Z = 3.02,(P =.003) Ellis et al, 4 2002 Engström et al, 30 2010 Feinberg et al, 33 2000 Hillis et al, 11 2005 Kaneko et al, 56 2014
MacHaalany et al, 43 2014
López-Pérez et al, 42 2014 García-Cosío Carmena, 53 2017 Bursi et al, 10 2005 Cioffi et al, 13 2005 Uddin et al, 54 2012
Severe SMR vs No SMR Barra et al, 27 2012 Ellis et al, 4 2002 Engström et al, 30 2010 Mentias et al, 44 Koelling et al, 39 2002 Test for subgroup differences: χ 2 = 11.96, (P =.003); I 2 = 83.3%
Mentias et al, 44 2017 Persson et al, 50 Shown are random-effects risk ratios and 95% CIs for all-cause mortality according to SMR grade. 4, 8, 10, 11, 13, 16, 27, 30, 33, 34, 39, [42] [43] [44] 50, 51, 54, 56, 58, 59, 62 NA indicates not applicable.
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Survival and Cardiovascular Outcomes of Patients With Secondary Mitral Regurgitation SMR (12 studies, 11 896 patients; RR, 2.62; 95% CI, 1.87-3.69; P < .001, I 2 = 74%). These results are shown in eFigure 2 in the Supplement.
Composite End Point of Death, HF Hospitalization, and Cardiac Transplant
In patients having SMR, the incidence of the composite end point of death, HF hospitalization, and cardiac transplant was significantly higher compared with patients not having SMR (11 studies, 8256 patients; RR, 1.63; 95% CI, 1.33-1.19; P < .001, I 2 = 78%) (eFigure 3 in the Supplement). When the analysis was stratified according to the degree of SMR, all subgroups demonstrated a significant association between the presence of SMR and the composite end point, with no differences between subgroups (χ 2 = 5.12, P = .08).
Study Quality Assessment and Heterogeneity
Heterogeneity refers to the variation in study outcomes between studies. To assess the influence of study quality (bias) on heterogeneity, we applied the Newcastle-Ottawa Scale 18 for quality assessment to the primary studies included in the meta-analysis. All included studies fell into the low or medium categories of risk of bias (eTable 5 in the Supplement), allowing us to identify 2 subgroups (low or medium) and to perform a subgroup analysis of our primary outcome.
Sensitivity Analysis
The significantly higher incidence of all-cause mortality in the patients with SMR vs the patients without SMR was confirmed when meta-analyses were repeated by removing 1 study at a time (eTable 6 in the Supplement). All the additional sensitivity analyses performed were consistent with the previous results (eTable 7 in the Supplement). Moreover, the analysis of all-cause mortality was repeated using a fixed-effects model, which confirmed the significantly higher mortality rate in the patients with SMR vs the patients without SMR (eFigure 4 in the Supplement). Our results were consistent even when the analysis for the primary outcome was performed with inclusion of only the studies reporting adjusted estimates (eTable 7 and eFigure 5 in the Supplement). Finally, when the primary end point was tested in specific subgroups of patients with ischemic or idiopathic cardiomyopathies, the presence of any degree of SMR was consistently associated with a significantly higher all-cause mortality in both subgroups (eFigure 6 in the Supplement). Subtotal (95% CI) Heterogeneity: Not applicable Test for overall effect: Z = 2.04, (P =.04)
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Shown are random-effects risk ratios and 95% CIs for all-cause mortality according to SMR grading. 2, 14, 15, [24] [25] [26] 28, 32, 45 The cutoff for EROA is 0.2 cm 2 , and the cutoff for regurgitant volume is 30 mL. EROA indicates effective regurgitant orifice area; NA, not applicable; VCW, vena contracta width.
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Meta-regression Analysis and Publication Bias
To explore the potential influence of modifiers on the association between SMR and the all-cause mortality outcome, we performed a meta-regression analysis of the baseline characteristics of the included studies. Meta-regression analysis showed no relationship between all the analyzed effect modifiers and the primary outcome of interest (P > .05 for all) except for the covariates of New York Heart Association (NYHA) class III or IV and length of follow-up (eTable 8 and eFigure 7 in the Supplement).
The funnel plots did not show any publication bias for all the analyses performed. These results are shown in eFigure 8 and eFigure 9 in the Supplement.
Discussion
To our knowledge, this study is the first comprehensive metaanalysis that includes a large number of studies on survival and cardiovascular outcomes in patients with ischemic or dilated cardiomyopathies and SMR. The results of this study demonstrate the following findings: (1) patients seen with SMR have higher rates of all-cause mortality, HF hospitalization, cardiac mortality, and a composite end point of death, HF hospitalization, and cardiac transplant; (2) this observation held true independent of how SMR had been detected (left ventriculography or echocardiography) or graded (qualitatively or quantitatively); (3) even patients with mild SMR have a worse prognosis; (4) higher grades of SMR severity are associated with worse LV dysfunction; (5) higher all-cause mortality persisted in patients with SMR and ischemic vs nonischemic cardiomyopathy; and (6) in studies with a higher prevalence of NYHA class III or IV HF symptoms and in studies with longer follow-up, the relationship between SMR and all-cause mortality was attenuated.
Secondary mitral regurgitation is the most common valve disease worldwide; however, its relationship with prognosis and its treatment have been a matter of debate. 63 not showing a mortality difference. Secondary mitral regurgitation is dynamic and strongly dependent on loading conditions; moreover, all methods to quantify SMR have inherent strengths and weaknesses, rendering accurate quantification of SMR challenging. Current guidelines recommend integration of multiple qualitative and quantitative parameters to determine severity as opposed to simple eyeballing of MR jet size. 64 However, this recommendation is seldom followed in practice and was not specified in the Methods section of most of the studies included in this metaanalysis, which could explain the high disparity in the results. In the present meta-analysis, there was considerable diversity in the methods used to grade SMR severity (eTable 4intheSupplement). Most of the included studies used echocardiography to detect SMR and a variable spectrum of parameters to grade it; SMR was detected by left ventriculography only in a few studies. [3] [4] [5] 9, 36, 41, 48, 52 In our meta-analysis that pooled together 53 studies and 45 900 patients with ischemic or nonischemic cardiomyopathies, patients with SMR displayed an increased risk of allcause mortality, hospitalization for HF, cardiac death, and a composite end point of death, HF hospitalization, and cardiac transplant. Even patients with mild SMR experienced a 1.36-fold increase in all-cause mortality (Figure 3) . Although there was fairly high heterogeneity in our analyses, our results were confirmed by the leave-one-out sensitivity analysis, by the additional sensitivity analyses, and by repeating the main analysis with a fixed-effects model. Moreover, no matter how SMR was detected or graded, patients with ischemic or idiopathic cardiomyopathies and any degree of SMR appear to have worsened survival (Figure 4) . Notably, as a result of our meta-regression analysis, the association between SMR and all-cause mortality was attenuated in the studies with longer follow-up. A possible explanation might be that patients with ischemic or dilated cardiomyopathies will eventually die of their disease regardless of the presence or absence of SMR if followed up for many years. Moreover, in patients with more symptomatic HF (NYHA III-IV), the presence of SMR seemed to be less predictive of all-cause mortality. A potential explanation is that, in highly symptomatic patients, HF or worsened LV systolic and diastolic function may dominate the prognosis relative to MR severity (eFigure 7A in the Supplement). This is a critical point because, by definition, SMR is a consequence of LV dysfunction. Therefore, SMR may be a surrogate for more extensive LV dysfunction or HF symptoms rather than causal. Indeed, it has been previously shown that, in patients with HF and low LVEF, the severity of SMR is related to the severity of LV dysfunction. 6 The present meta-analysis confirms this observation; in 26 of the 36 studies that reported LVEF according to SMR grade, LV systolic function was significantly worse in patients having moderate or severe SMR compared with patients having only mild or absent SMR. In the remaining 10 studies, the association was not statistically significant ( Figure 2 and eTable 3 in the Supplement). Because the hemodynamic effects of MR are known to augment LVEF, the observed decline in LVEF with increasing MR grades is somewhat unexpected and suggests that patients with SMR have worse LV myocardial function than implied from LVEF measurement alone. Therefore, it is important to acknowledge that SMR may be a marker of risk due to greater LV dysfunction rather than a cause of mortality.
Limitations
This meta-analysis has several limitations. Secondary mitral regurgitation is a dynamic condition and may change over time in individual patients. Moreover, SMR detection and grading differed across the included studies, which could have led to an interpretation bias. However, given the large number of studies and patients included, this limitation may be irrelevant. Various populations are included in this meta-analysis, and this factor might account for the differences in outcomes. This is why we performed sensitivity and subgroup analyses to rule out most of the differences in subgroup populations. There is a fairly high degree of heterogeneity in the performed meta-analysis. However, the consistency of our results was confirmed by both the sensitivity analyses (eTable 6 and eTable 7 in the Supplement) and by using a fixed-effects model for the primary outcome of interest (eFigure 4 in the Supplement). Despite the association of SMR with mortality, there is no convincing evidence that surgical or percutaneous correction of SMR is superior to medical therapy. 6 63 The present meta-analysis could not distinguish those patients because accurate data on LV volumes and sphericity and regional wall motion were not available in most of the studies.
The observation that even mild SMR is associated with an adverse prognosis had been used as a reason to lower the threshold values for defining severe SMR by echocardiographic measurements of effective regurgitant orifice area and regurgitant volumes. The recent update to the guidelines has reiterated that the threshold for defining severe SMR is the same as for primary MR, partly to prevent unnecessary operation due to overestimation of the severity of SMR and the lack of proof that surgery improves outcomes. 66 Grading of SMR severity is complicated by the fact that the amount of SMR resulting in significant loss of forward stroke volume is related to LV volumes and LVEF and thus may be different in smaller patients, particularly women.
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Conclusions
The large number of studies and patients in this metaanalysis demonstrate clear findings that SMR may be a marker of adverse outcomes independent of how it has been detected or graded. However, because SMR is an intrinsic consequence of LV dysfunction, causality between SMR and mortality should not be implied. Treatment is more enigmatic for secondary MR, which is often caused by left ventricular (LV) dysfunction and dilation that leads to a distortion of the mitral apparatus and restricted closure of otherwise normal mitral valve leaflets. As this is more a disease of the ventricle than of the valve, surgical valve repair is often not durable unless the LV remodeling can be halted or reversed, and identifying those who will benefit from undergoing surgery remains imprecise and problematic. The fundamental uncertainty is whether secondary MR is associated with, or contributes to, worse clinical outcomes among patients with LV systolic dysfunction.
In this issue of JAMA Cardiology, Sannino and colleagues 3 present the results of a meta-analysis of 53 studies involving 40 900 patients with ischemic or dilated cardiomyopathy. Those with secondary MR had significantly greater mortality rates and risk of heart failure hospitalization over a mean (SD) follow-up period of 41 (22) months compared with those without MR. Greater severity of MR, whether assessed qualitatively or quantitatively, was related to worse clinical outcomes, but importantly, even mild degrees of MR were associated with reduced survival rates compared with those with no MR. This contrasts with primary MR, in which mild degrees of MR are tolerated for years without prognostic detriment. These data from Sannino and colleagues 3 support the concept that secondary MR identifies higher-risk patients with ischemic or dilated cardiomyopathy. As LV dysfunction and remodeling are the underlying mechanisms for secondary MR, Sannino and colleagues 3 also identify the key link between the presence and severity of secondary MR and the severity of LV dysfunction. In the 36 studies in this report that evaluated LV function, patients with secondary MR had lower ejection fractions than those without MR, and greater severity of MR was associated with worse LV function. 3 Whether secondary MR is merely a marker of severity of LV dysfunction or actually contributes to declining LV function in some patients-and is thus a target for therapy-remains uncertain. We know that guideline-directed medical therapy is associated with improved survival rates among patients with LV dysfunction, and the associated reverse remodeling reduces the severity of secondary MR. This supports current recommendations that the principal management of secondary MR is to first treat the underlying LV dysfunction with guideline-directed medical therapy including, in appropriate patients, cardiac resynchronization therapy. 1, 2 Further investigation is needed to determine whether surgical or transcatheter procedures that are directed at reducing secondary MR improve outcomes compared with guideline-directed medical therapy alone. 8 Echocardiography maximum regurgitant jet area >30 days after acute MI Bursi F. 9 Echocardiography maximum regurgitant jet area CHF Calafiore AM. 10 
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